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“We will have tougher negotiations, more competition and much lower prices at the pharmacy 
counter and it will start to take effect very soon," Donald J. Trump said in his speech describing 
his Blueprint to Lower Drug Prices and Reduce Out-Of-Pocket Costs. 
The Department of Health and Human Services (HHS) has taken a number of actions to increase 
competition and end the gaming of regulatory processes that may keep drug prices artificially 
inflated or delay generic, branded, or biosimilar competition. These efforts, which were in 
motion before announcement of the blueprint, include increasing the number of generic drugs 
and accelerating approval of generic drugs.1  
Studies show that greater generic competition is associated with lower prices. Based on a study 
in 2017, the relative price of a generic medication to the branded medication decreases 
appreciably when there are 3 or more manufacturers of the generic version. The researchers 
found that the relative generic-to-brand price was 87%, 77%, and 60% when there were 1, 2, and 
3 generic manufacturers, respectively. With each additional manufacturer, the relative prices 
decreased at a slower rate.2  
Over 1,000 generic drugs were approved in 2017, the highest annual total in FDA’s history. 
While these generic approvals saved American consumers nearly $9 billion in 2017, there are 
still drugs with inadequate generic competition. To that end, the Food and Drug Administration 
(FDA) is publishing the names of drugs that have no competitors to motivate manufacturing and 
bring prices down.1 In fact, the FDA has highlighted potassium chloride oral solution, for 
instance, as one of the drugs that could benefit from competitors.3  
Based on the FDA’s Drug Competition Action Plan in 2017, the agency is focusing on different 
ways to enable patients to access more affordable medications. These techniques include 
“improving the efficiency of the generic drug development, review, and approval process; 
maximizing scientific and regulatory clarity with respect to complex generic drugs; and closing 
loopholes that allow brand-name drug companies to “game” FDA rules in ways that forestall the 
generic competition Congress intended”.1 Generic EpiPen is an example of a new generic that 
has emerged in the market recently with lower prices for patients.4  In one of the latest updates in 
September this year, the FDA issued 54 product specific guidance to promote generic drug 
access and drug price competition.5 
Furthermore, the Blueprint proposes steps to prevent manufacturer gaming of regulatory 
processes such as Risk Evaluation and Mitigation Strategies (REMS). Historically, the FDA may 
impose REMS requirements on a drug to ensure its benefits outweigh its risks, and a REMS 
program may require restrictions on distribution of the drug, as well as mandated education for 
providers and patients. Although current law already prohibits use of REMS to "block or delay" 
approval of a generic drug, the Blueprint suggests the FDA will consider additional steps 
intended to prevent innovators’ use of REMS requirements to impede generic entry.1 
The Blueprint also explains that the FDA will issue policies to improve “the availability, 
competitiveness, and adoption of biosimilars as affordable alternatives to branded biologics." 
The Blueprint notes that FDA will continue its educational efforts directed at clinicians, patients, 
and payers about biosimilar and interchangeable products. Like non-biologic drugs, biologics are 
regulated by the FDA and are used to prevent, and treat diseases, for example, many cancers, 
rheumatoid arthritis, diabetes, and multiple sclerosis. However, the costs of these products have 
continued to increase, as has their share of U.S. drug spending. 
The Biologics Price Competition and Innovation Act (BPCI) was enacted in 2010 with the intent 
of “balancing innovation and consumer interests” by creating an abbreviated pathway for the 
approval of biologics demonstrated to be biosimilar to, or interchangeable with, an FDA-licensed 
reference product. In contrast to most drugs that are chemically synthesized and their structure 
well-characterized, most biologics are complex proteins or other by-products of living cells. 
Their safety and effectiveness can be affected by small changes in manufacturing, packaging, or 
storage. FDA standards for evaluating proposed biosimilar incorporate new tools for assessing a 
biosimilar’s structural and functional properties relative to the reference product. The agency 
continues to look for ways to ensure reference product manufacturers are not using FDA 
requirements to unfairly delay the entry of biosimilars.1,6 
Hopefully, these proposals and new actions to increase competition will change our current drug 
market and help patients access medications at a lower cost. 
Next month, our pharmacists will take a closer look at how better negotiation can improve drug 
prices. 
Read the previous blog in this series from Bonnie Greenwood, PharmD, BCPS, who gives an 
overview of the Trump Administration's blueprint to tackle rising drug costs.  
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